"Rosenpark Research ist ein unabhängiges Forschungsinstitut im Zentrum Darmstadts und führt klinische Studien im Bereich Dermatologie durch."

During the past decade, Rosenpark Research GmbH conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 10 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 9 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rosenpark Research GmbH" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Galderma R&D" with 2 trials sponsored, "Ipsen" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Medy-Tox" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rosenpark Research GmbH" #1 collaborator was "Dermira, Inc." with 3 trials as a collaborator, "Incyte Corporation" with 3 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator and "TFS Trial Form Support" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Rosenpark Research GmbH" are "Atopic Dermatitis" (7 trials), "Psoriasis" (4 trials), "Glabellar Lines" (3 trials), "Plaque Psoriasis" (3 trials) and "Lateral Canthal Lines" (2 trials). Many other conditions were trialed in "Rosenpark Research GmbH" in a lesser frequency.

Most popular intervention types in "Rosenpark Research GmbH" are "Drug" (16 trials), "Biological" (7 trials), "Device" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Baricitinib" (3 trials), "Lebrikizumab" (3 trials), "JNJ-77242113" (2 trials) and "MT10109L" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rosenpark Research GmbH" are 23 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Rosenpark Research GmbH". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Rosenpark Research GmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Rosenpark Research GmbH, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".